New scout dose method could make liver cancer radiation safer for lungs
NCT ID NCT07476651
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new method to check if a liver cancer treatment called radioembolization is safe for the lungs. Currently, doctors use a test particle (MAA) to estimate lung radiation risk, but it may not be perfectly accurate. The new method uses a small 'scout dose' of the actual treatment beads (Y-90 microspheres) and a PET/CT scan to get a more precise measurement. The study will enroll 30 adults with liver tumors to compare the two approaches.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Yttrium-90 resin microspheres (SIR-Spheres)
What this could lead to
If successful, this could make radioembolization safer by more accurately measuring how much radiation reaches the lungs, and provide a reliable alternative when the current test is unavailable.
What could go wrong
This is a small early study with only 30 participants, so results may not apply to everyone. The extra procedure adds time and discomfort, and the scout dose itself carries a small radiation risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••